2 Information about elosulfase alfa

Marketing authorisation indication

2.1 Elosulfase alfa (Vimizim, Biomarin) is licensed to treat 'mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for elosulfase alfa.


2.3 The price for elosulfase alfa is £750 per 5‑mg vial (excluding VAT; BNF online accessed October 2021). The company has a commercial arrangement. This makes elosulfase alfa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)